Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Real-time Estimate Cboe BZX  -  10:42 2022-10-06 am EDT
231.71 USD   -0.90%
09:01aAmgen opens new state-of-the-art research and development laboratory site in san francisco bay area
PR
07:45aRBC Trims Price Target on Amgen to $235 From $236, Maintains Sector Perform Rating
MT
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RBC Raises Price Target on Amgen to $236 From $224, Cites 'Another Quarter of Solid Execution,' Maintains Sector Perform Rating

08/05/2022 | 07:51am EDT


© MT Newswires 2022
All news about AMGEN INC.
09:01aAmgen opens new state-of-the-art research and development laboratory site in san franci..
PR
07:45aRBC Trims Price Target on Amgen to $235 From $236, Maintains Sector Perform Rating
MT
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/21EU approves AstraZeneca-Amgen treatment for severe asthma
RE
09/19Novartis' Biosimilar for Osteoporosis Drug Xgeva Matches Reference Therapy in Safety, E..
MT
09/16Amgen : Is Ready to Meet Growing Demand for Innovative Medicines, Says Bradway in Bloomber..
PU
09/15Consumer group says drugmakers abuse U.S. patent system to keep prices high
RE
09/15Transcript : Amgen Inc. Presents at BofA Securities Global Healthcare Confere..
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 145 M - -
Net income 2022 6 293 M - -
Net Debt 2022 27 027 M - -
P/E ratio 2022 19,8x
Yield 2022 3,32%
Capitalization 125 B 125 B -
EV / Sales 2022 5,82x
EV / Sales 2023 5,53x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 233,82 $
Average target price 249,81 $
Spread / Average Target 6,84%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.3.93%125 078
JOHNSON & JOHNSON-3.48%434 104
ELI LILLY AND COMPANY19.43%315 249
ROCHE HOLDING AG-13.48%273 724
ABBVIE INC.5.86%253 421
PFIZER, INC.-25.28%247 617